Article Sidebar
Views pdf: 81
SURVIVAL OUTCOMES AND RELATED FACTORS IN FIRST-LINE OSIMERTINIB TREATMENT FOR ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER
Main Article Content
Abstract
Objectives: To evaluate the progression-free survival (PFS) and related factors in first-line osimertinib treatment for patients with advanced-stage non-small cell lung cancer (NSCLC) harboring EGFR mutations. Patients and method: A descriptive study combining retrospective and prospective data collection was conducted on 128 patients with advanced-stage EGFR-mutant NSCLC who received first-line osimertinib treatment at K Hospital from April 2019 to December 2023. PFS and related factors were analyzed. Results: The median PFS was 24.5 months. The progression-free survival rates at 1 year, 2 years, and 3 years were 90%, 53.6%, and 48.2%, respectively. Patients with good performance status (PS 0–1) had significantly longer PFS compared to those with poor performance status (PS ≥ 2) (p=0.005). Conclusion: First-line osimertinib demonstrated favorable progression-free survival outcomes in patients with advanced EGFR-mutant NSCLC. Performance status was identified as a significant factor associated with prolonged PFS.
Article Details
Keywords
non-small cell lung cancer, EGFR-mutated, osimertinib
References
2. Trần Văn Thuấn LVQ, Nguyễn Tiến Quang. “Ung thư phổi”. Hướng dẫn chẩn đoán và điều trị một số bệnh ung thư. 2019:176-187.
3. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378: 113.
4. Zhang D, Liu X, Shen F, et al. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. Transl Lung Cancer Res. 2023 Nov 30;12(11):2229-2244.
5. Watanabe K, Yoh K, Hosomi Y, et al. Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study. BMJ Open. 2022 Jan 4;12(1):e046451.
6. Lorenzi M, Ferro A, Cecere F, et al. First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist. 2022 Mar 4;27(2):87-e115.
7. Sakata Y, Sakata S, Oya Y, et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer. 2021 Dec;159:144-153.
8. Gen S, Tanaka I, Morise M, Koyama J, Kodama Y, Matsui A, Miyazawa A, Hase T, Hibino Y, Yokoyama T, Kimura T, Yoshida N, Sato M, Hashimoto N. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC Cancer. 2022 Jun 14;22(1):654.